Abstract: Objective To explore the short-term and long-term efficacy of tyrosine kinase inhibitors (TKI) combined with hepatic artery chemoembolization (HAC) for the treatment of hepatocellular carcinoma (HCC). Methods The study focused on 60 HCC patients collected at Zongyang County People's Hospital from June 2019 to June 2021. The patients were divided into a treatment group and a control group with 30 cases in each group using a random number table method. The treatment group received TKIs combined with HAC treatment, while the control group received traditional hepatic artery chemoembolization treatment.The treatment efficacy, liver function, serum AFP levels, survival time, safety, etc, were evaluated. Results Following the treatment, the treatment group exhibited a higher proportion of CR and PR compared to the control group (90.00% vs. 66.67%, P<0.05). After 6 weeks of treatment, the ALT was 40.92 ± 6.09 (U/L), which was lower than the control group's 46.33 ± 8.13 (U/L); After 9 weeks of treatment, the serum AFP level in the control group was 153.25 ± 42.23 μg/L, which was higher than the treatment group's 74.61 ± 18.29 μg/L; The progression free survival of the treatment group was 22.41 ± 2.88 months, with a total survival of 34.18 ± 5.77 months. The progression free survival of the control group was 14.17 ± 3.14 months, the overall survival in the study group was 21.68 ± 5.36 months. There were no statistically significant difference in the incidence of adverse reactions was observed between the two groups (P>0.05). Conclusion The combination of TKIs and HAC treatment for HCC has shown good therapeutic effects in short and long term, which has clinical promotion value.

Key words: hepatocellular carcinoma, Hepatic artery chemoembolization, Tyrosine kinase inhibitors, Quality of life, curative effect